Case reportPublished 27 May 2020
Alemtuzumab-Induced Inflammatory Bowel Disease in a Multiple Sclerosis Patient
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Alemtuzumab produces a total depletion and posterior repopulation of T and B cells. Autoimmunity is an important adverse event of this drug. In recent years, other autoimmune diseases, different to thyroid, kidney and platelets alterations have been described. Clinical Case: We present one case of alemtuzumab-treated multiple sclerosis patient who develops ulcerative colitis after two cycles of alemtuzumab. Conclusion: To our knowledge, no cases have been published in the literature, which relate alemtuzumab with the development of ulcerative colitis. The different kinetics in B and T cells repopulations and the change in the gut microbiota induced by alemtuzumab or by changes in diet to prevent listeriosis, could increase the risk of developing this autoimmune phenomenon.
Keywords
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalNeurological Disorders
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Jose Vicente Hervas Garcia”
- BylineArticles whose byline prints “Gisela Torres-Vicente”
- BylineArticles whose byline prints “Cristina Gonzalez-Mingot”
- BylineArticles whose byline prints “Anna Gil-Sanchez”
- BylineArticles whose byline prints “Lara Nogueras”
- BylineArticles whose byline prints “Silvia Peralta”
- BylineArticles whose byline prints “Maria Jose Solana”
- BylineArticles whose byline prints “Luis Brieva”
